NDAORAL-21TABLET
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LOESTRIN 21 1.5/30 (ethinyl estradiol; norethindrone acetate) by Teva. Approved for pregnancy. First approved in 1976.
Drug data last refreshed 4d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOESTRIN 21 1.5/30 is an oral contraceptive tablet containing ethinyl estradiol and norethindrone acetate, approved in 1976 for pregnancy prevention. It is a combined estrogen-progestin formulation that prevents ovulation through hormonal suppression. The product represents a legacy small-molecule contraceptive in a mature, competitive market.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; teams are typically in maintenance or defensive mode with limited growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on LOESTRIN 21 1.5/30 as a pharma professional offers limited growth potential given the product's LOE-approaching lifecycle and zero linked job postings. Roles are defensive in nature, focused on maintaining market position and managing generic competition rather than innovation or expansion.
Brand Manager
Worked on LOESTRIN 21 1.5/30 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.